Clinical Research Directory
Browse clinical research sites, groups, and studies.
Transcatheter Treatment of Tricuspid Valve Regurgitation
Sponsor: TriFlo Cardiovascular, Inc.
Summary
Tricuspid Regurgitation induces an asymmetric enlargement of the tricuspid valve (TV) annulus causing a reduction of leaflets coaptation. Annular dilation continues even after surgical treatment. The progressive nature of TR, inadequate surgical treatment, and high-risk patient population make TR an ideal target for transcatheter therapy. The TriFlo TFO System introduces a new concept for the treatment of tricuspid regurgitation. Its commissural anchoring is designed to respect TV leaflet integrity, mobility, and maintain RV contractility.
Official title: Transcatheter Treatment of Tricuspid Valve Regurgitation With the TriFlo Tricuspid Flow Optimizer (TFO) System
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-10
Completion Date
2031-12
Last Updated
2023-10-23
Healthy Volunteers
No
Interventions
TriFlo Tricuspid Flow Optimizer
An introducer sheath is inserted into the femoral vein over a stiff guidewire; the sheath extends into the common iliac vein and inferior vena cava and in the right atrium. The TFO device is oriented coaxiality to the tricuspid. Once released, the delivery catheter and the steerable catheter are removed the access site closure performed by a cardiovascular or vascular surgeon or with pre-implanted percutaneous sutures per site preference.
Locations (4)
Pineta Grande Hospital
Castel Volturno, Caserta, Italy
IRCCS Humanitas Research Hospital
Rozzano, Milano, Italy
IRCCS Policlinico San Donato
San Donato Milanese, Milano, Italy
Policlinico Campus Biomedico
Roma, Italy